

Outcome Results from
**Real Life
 Big Data Studies**

Mon. November 16, 2015
The Peres Center for Peace
 132 Kedem St. Tel Aviv-Jaffa

oncotype DX[®]
 Breast Cancer Assay

Tests worldwide:

600,000

Tests in Israel:

12,000

17:30-18:30	Cocktail & Dinner Reception
18:30-19:00	Greetings & Opening Remarks
19:00-19:30	Practical Applied Genomics in Early Breast Cancer: The Development and Validation of Oncotype DX Norman Wolmark, M.D. Chairman and Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP), Professor and Chairman of Human Oncology, Drexel University School of Medicine Philadelphia, Pennsylvania.
19:30-20:00	TAILORx and the Power of Prospective Outcomes Data Steve Shak, M.D. Executive Vice President of Research and Development, Genomic Health Inc.
20:00-20:20	Real-life Analysis Evaluating Treatments and Outcomes in Clalit Breast Cancer Patients for whom Adjuvant Treatment Decisions Incorporated the 21-gene Recurrence Score Results (Median Follow-up >5 Years) Salomon M. Stemmer, M.D. Head, Research Unit, Institute of Oncology, Davidoff Center, Rabin Medical Center. Affiliated to the Sackler Faculty of Medicine.
20:20-20:45	Questions & Discussion
20:45-21:15	Desserts & Good bye

Norman Wolmark, M.D.

Chairman and Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP) which is funded by the NCI and is based on the campus of Allegheny General Hospital in Pittsburgh, Pennsylvania. He is also Prof. of Surgery at the Temple University School of Medicine and is a breast surgeon at Allegheny General Hospital, Pittsburgh, Pennsylvania.

Prof. Wolmark gained his MD at McGill University, Montreal, Canada and he subsequently completed his residency at the University of Pittsburgh. Prof. Wolmark was then appointed to the position of Cancer Expert at the Surgery Branch of the National Cancer Institute, Bethesda, Maryland. Prof. Wolmark is a member of numerous professional societies, including the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the American Surgical Association (ASA).

He is a reviewer for the Journal of Clinical Oncology and the New England Journal of Medicine, and he also serves on numerous boards and as an advisor to oncology programs, societies and institutes throughout the United States, Europe and Asia.

Steve Shak, M.D.

Executive Vice President of Research and Development, Genomic Health Inc. Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as the Executive Vice President of Research and Development since 2012 and was the Chief Medical Officer from 2000-2013.

Under Steve's leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX[®] breast cancer and colon cancer assays and has maintained an 80% product development success rate.

Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in Discovery Research and Medical Affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.

Steve led the clinical team that gained approval for Herceptin[®], a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin[®]. In addition, Steve discovered Pulmozyme[®], a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis.

Prior to joining Genentech, Steve was an Assistant Prof. of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco.

Salomon M. Stemmer, M.D.

An expert in cancer therapy and palliative care medicine, Prof. Stemmer is the Head of the Research Unit of the Division of Oncology, Davidoff Center, Rabin Medical Center, affiliated to the Sackler School of Medicine (Associate Clinical Prof.) Tel Aviv University, Israel.

Prof. Stemmer was trained by Dr. James Holland in Mt. Sinai, New York, and worked several years at the University of Colorado Health Sciences Center. Prof. Stemmer is leading translational research efforts in cancer therapy (Phase I-II trials) and research regarding treatment related toxicity. He treats the patient as a whole: deals with the complexity of the patient with a malignant process, using novel approaches based upon precise medicine, taking into account tolerability of treatment, risk-benefit ratio and quality of life.

Prof. Stemmer advises to pharmaceutical and start-up companies in the development of new anti cancer agents, delivery methods etc.

He has published over 80 peer reviewed papers in leading oncology and science journals.

To confirm your participation please register:

Email: Oncotest@el-dan.co.il | R.S.V.P: 050-4252072 Eldan